Trodelvy fails PhIII lung cancer study in blow to Gilead’s ADC expansion plans

Gilead’s antibody-drug conjugate Trodelvy failed to significantly extend survival in a late-stage lung cancer study, the pharma company said Monday morning.

The Phase III EVOKE-01 study looked at Trodelvy in second-line metastatic non-small cell lung cancer. It’s the first pivotal readout for the TROP2 antibody-drug conjugate in lung cancer, a…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks